[Advances in Alzheimer's disease treatment].
Nourhashémi
F
F
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D000077265:Donepezil; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D005702:Galantamine / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008559:Memantine / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use*; D048448:Phenylcarbamates / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D000068836:Rivastigmine
D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D007189:Indans; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D010919:Placebos; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine; D008559:Memantine